• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1277126 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
6 Q0 }& z- Y. j. ^0 DNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% v+ F+ O8 x1 n' l3 f1 N( i+ Author Affiliations6 L2 B, m; \% h

+ U$ \0 r5 ^' \6 [' C1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3 r- [" b/ L+ R1 T* E1 C7 ]2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " x, r$ W9 F( _3 w7 b
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 I# i8 ~, f/ ~. j) |
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
, P2 X% c0 H  @/ @: d$ @5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
* n- I$ |5 M& U, [. s/ Q9 K& A6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 u1 [. J$ R% s6 }% Q3 u' d
7Kinki University School of Medicine, Osaka 589-8511, Japan
5 h. X7 M6 g/ _% N# D, U8Izumi Municipal Hospital, Osaka 594-0071, Japan
+ \. o9 k2 |! J9 @0 G  l. }9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 I; C" k! n! Z# {/ {) d7 }
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
" K# t) [, \6 eAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* q5 Q" g; d; v  r% n; @2 [8 F# z: |' w. p& t- f4 i$ v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
) Y' V: Y+ {+ E. ?
% ^! B0 s4 E# z3 C5 T5 gAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 8 ~  I6 }+ j( q7 A1 q6 \0 B: {
2 l: j- s3 C( s6 J% F" k* f
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  2 c& E" L. ^5 ]. @: Y; W; ^0 f

' {) ]( U  [; K' E8 H% V" pPublished online on: Thursday, December 1, 2011
2 a2 @# O! S; m5 V
2 J2 p" o/ n& y) [) r% q9 a( ]! yDoi: 10.3892/ol.2011.507
+ a' ^  F: N/ r) G) [/ t! W
/ I8 T9 t) N* c5 a4 W6 fPages: 405-410
% ^6 o  i6 r: m( R6 i6 f9 x8 |5 N* s3 F6 X! g2 ?
Abstract:, f$ Y8 @9 Y* W4 B. W
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
- [  j- ~1 p# y" V8 S: V7 G 3 K) V( a5 K2 t: }% J( S$ f$ _  q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population+ B4 f2 E: O  v; l$ ^4 _8 a" v
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
) i& _' P4 B% F: N( f5 _+ Q+ Author Affiliations
2 p+ s5 D" A3 q9 f. ~. R1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
9 K& X  p# X* ?- F7 E: {. D2Department of Thoracic Surgery, Kyoto University, Kyoto ' g2 P+ `9 G1 Z( D: A* q
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ) O5 a1 G" l& |! I- g- d$ o8 E
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp + s  U& L! q) z0 Q- `) M2 y- D
Received September 3, 2010. + r9 q: g0 R' ^' v
Revision received November 11, 2010. - M% c* Q) N6 o, i
Accepted November 17, 2010.
$ {1 R: B" m; @. k5 d8 eAbstract
6 {# q' I' ?/ b4 H5 ~3 k) R9 ^& I* ]Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
- x8 R4 h! q: G: cPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 1 b/ S# E7 C! k( A6 S
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
( w0 x( v* y% g& o2 C+ G6 d4 T2 WConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. : \7 w) i" z, d' `& v
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。( k3 J9 `, A3 R
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
3 D! G2 ?6 ]$ p$ V
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
% o. K# n% c' Uhttp://clinicaltrials.gov/ct2/show/NCT01523587( `/ F) p) D. i# V. `2 g8 `5 i

* ~9 n3 I- h  k( Y4 a" VBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC1 r* c0 m* Z/ R8 u9 g( x
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑   I3 F. ?: s7 v( ?

- a, K2 D) E  @9 d( J, y4 C6 a从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。4 K+ a1 ^* M! x1 z; ^" b2 ^
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 $ i9 f0 j; r7 s0 ^/ {: A& U
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 F8 s1 S: m2 `5 Q  L/ O8 t
至今为止,未出 ...
( h2 b7 [" i; @+ j# x- N6 C
没有副作用是第一追求,效果显著是第二追求。8 |. k/ O  K* t9 t6 ?4 Z
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表